CHMP backs approval of Veltassa, other candidates

On Friday, EMA's CHMP recommended approval of several therapies, including hyperkalemia drug Veltassa patiromer, psoriasis drug Kyntheum brodalumab and schizophrenia treatment Reagila cariprazine. The committee also issued a negative opinion for colorectal cancer candidate Xilonix from XBiotech Inc. (NASDAQ:XBIT).

CHMP backed approval of Veltassa from Vifor Pharma Ltd. (SIX:VIFN) to treat hyperkalemia in adults. The high-capacity oral potassium binder is approved in the U.S. for the indication. Vifor obtained the drug via its acquisition in 2016 of Relypsa Inc...